La chaîne d'options affiche les données clés des options sur actions de Galmed Pharmaceuticals à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Galmed Pharmaceuticals..

Galmed Pharmaceuticals (NASDAQ:GLMD) Stock, Chaîne d'Options

Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals Ltd

Small Cap

Press Releases

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

News

Emerging Growth Leaders: – INEO, PLUG, HIT, GLMD, OMEX, More Stocks Inside – Health, Energy, Mining, and Defense Making Headlines

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models

Earnings

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

GLMD

INEO

OMEX

PLUG

PNPNF

PRSO

TSXV:PNPN

AIM ImmunoTech

Alzamend Neuro

Aprea Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Bio Green Med Solution, Inc. - Common Stock

Bio Green Med Solution

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Ensysce Biosciences

Entero Therapeutics

Ernexa Therapeutics

HCW Biologics

Kala Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Mainz Biomed

Neuphoria Therapeutics Inc. - Common Stock

Neuphoria Therapeutics

Polyrizon

PharmaCyte Biotech

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Comments

Galmed Pharmaceuticals

Galmed Pharmaceuticals (GLMD) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL